巨噬细胞线粒体质量控制在动脉粥样硬化中的作用研究进展  

Research progress on the role of macrophage mitochondrial quality control in atherosclerosis

作　　者：朱春燕 黎土娣 陈荣 陈恺曈 曾智桓[1] ZHU Chunyan;LI Tudi;CHEN Rong;CHEN Kaitong;ZENG Zhihuan(The Second Department of Cardiology,the First Affiliated Hospital of Guangdong Pharmaceutical University,Guangdong Province,Guangzhou510000,China)

机构地区：[1]广东药科大学附属第一医院心血管二科,广东广州510000

出　　处：《中国医药导报》2025年第10期59-63,68,共6页China Medical Herald

基　　金：广东省医学科研基金立项项目(B2024095);广州市科技计划项目(2025A03J3718);中西医协同“旗舰”医院专项院内课题(ZXYXTQJ202301)。

摘　　要：动脉粥样硬化(AS)是一种多因素相关的慢性炎症性疾病,被认为是多数心脑血管疾病的主要病理基础。巨噬细胞是AS病变的核心免疫细胞群,参与AS病变的各个阶段。线粒体是驱动巨噬细胞增殖、分化、激活和极化的重要细胞器。线粒体质量控制失衡是导致巨噬细胞代谢异常、氧化应激与炎症的关键环节,对AS的发生和发展具有重要影响,是AS的潜在治疗靶点。本文主要综述巨噬细胞线粒体质量控制在AS中的作用机制和治疗应用的最新进展,以期为AS临床和基础研究提供参考。Atherosclerosis(AS)is a multifactorial related chronic inflammatory disease that is considered to be the main pathological basis of most cardiovascular and cerebrovascular diseases.Macrophages,as the main immune cell population in AS lesions,are involved in all stages of AS lesions.Mitochondria are important organelles that drive macrophage proliferation,differentiation,activation and polarization.Imbalance of mitochondrial quality control is a key link leading to abnormal macrophage metabolism,oxidative stress and inflammation,which has an important impact on the occurrence and development of AS,and is a potential therapeutic target for AS.This article mainly reviews the latest progress in action mechanism and therapeutic application of macrophage mitochondrial quality control in AS,in order to provide reference for clinical and basic research on AS.

关 键 词：动脉粥样硬化 线粒体质量控制 巨噬细胞极化 细胞程序性死亡 

分 类 号：R543.5[医药卫生—心血管疾病]